within Pharmacolibrary.Drugs.ATC.N;

model N05AD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.00028333333333333335,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AD03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Melperone is a butyrophenone antipsychotic drug primarily used for the treatment of schizophrenia and other psychotic disorders. It has a relatively mild side effect profile compared to other antipsychotics. Melperone is not widely available or approved in many countries today, but has been used in Europe, especially Germany.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult subjects based on limited published data and general pharmacokinetic principles of butyrophenone antipsychotics. Specific population or condition details not available.</p><h4>References</h4><ol><li><p>Borgström, L, et al., &amp; Molander, L (1982). Pharmacokinetics of parenteral and oral melperone in man. <i>European journal of clinical pharmacology</i> 23(2) 173–176. DOI:<a href=&quot;https://doi.org/10.1007/BF00545974&quot;>10.1007/BF00545974</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7140807/&quot;>https://pubmed.ncbi.nlm.nih.gov/7140807</a></p></li><li><p>Molander, L, &amp; Borgström, L (1983). Sedative effects and prolactin response to single oral doses of melperone. <i>Psychopharmacology</i> 79(2-3) 142–147. DOI:<a href=&quot;https://doi.org/10.1007/BF00427801&quot;>10.1007/BF00427801</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6133301/&quot;>https://pubmed.ncbi.nlm.nih.gov/6133301</a></p></li><li><p>Kumar, S, et al., &amp; Kumar, S (2017). In silico repurposing of antipsychotic drugs for Alzheimer&#x27;s disease. <i>BMC neuroscience</i> 18(1) 76–None. DOI:<a href=&quot;https://doi.org/10.1186/s12868-017-0394-8&quot;>10.1186/s12868-017-0394-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29078760/&quot;>https://pubmed.ncbi.nlm.nih.gov/29078760</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AD03;
